Prospective Observational Study Of Geniculate Artery Embolization For Symptomatic Knee Osteoarthritis In A Cancer Population

Prospective Observational Study Of Geniculate Artery Embolization For Symptomatic Knee Osteoarthritis In A Cancer Population

To explore associations with demographics/clinical factors; assess trajectories via annual follow-up; evaluate healthcare utilization and barriers; oversample >10-year survivors.

Primary Objective To characterize the change in knee pain and functional disability following standard-of-care GAE in cancer participants with symptomatic knee osteoarthritis, as measured by mean change in the total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score from baseline to 12 months

Inclusion Criteria

1. Age ≥40 years with no upper age restriction, provided performance status permits procedural candidacy
2. Symptomatic mild-to-severe knee osteoarthritis (Kellgren-Lawrence grade 2-4) on radiographs within 6 months of enrollment
3. Chronic knee pain (NRS ≥4/10) for ≥3 months despite conservative treatment including steroid injections, physical therapy, and/or analgesic medications
4. Inadequate candidate for or refusal of surgical intervention (e.g., total knee arthroplasty) due to cancer-related comorbidities, ongoing treatment, or participants preference
5. Active cancer diagnosis (solid tumor or hematologic malignancy) confirmed at MD Anderson Cancer Center

Exclusion Criteria

• Active joint infection or suspected septic arthritis
• Life expectancy <6 months
• Prior knee arthroplasty in the index knee
• Coagulopathy or contraindications to angiography
• GFR <30 mL/min/1.73m²
• Peripheral artery disease with stenosis or occlusion of lower extremity vasculature (relative contraindication per SIR standards, given geniculate artery collateral perfusion role)
• Radiographically normal knee joint (KL grade 0-1) - alternative etiologies should be sought
• Known active autoimmune/inflammatory arthropathy (e.g., rheumatoid arthritis, psoriatic arthritis)
• Any medical condition or clinical abnormality that, per investigator judgment, precludes safe participation in and completion of the study